# US 2026/0293881 A1 · Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0293881 A1
- Document ID: US20260293881A1
- Status: Published application
- Kind: A1
- Application number: 19/693,356
- Filed: 2026-05-30
- Published: 2026-10-01
- Earliest claimed: 2018-04-27
- Assignees: Iovance Biotherapeutics, Inc.
- Applicants: Iovance Biotherapeutics, Inc.
- Inventors: Cecile Chartier-Courtaud; Krit Ritthipichai
- Web page: https://patentgrep.com/patent/US20260293881A1

## CPC

- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/515: CD3, T-cell receptor complex
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for producing a therapeutic population of genetically modified tumor infiltrating lymphocytes (TILs), comprising:
(a) obtaining a first population of TILs from tumor tissue of a patient;
(b) culturing the first population of TILs in a first culture medium comprising IL-2 to produce an expanded population of TILs;
(c) introducing into at least a portion of the expanded population of TILs, by a gammaretroviral or lentiviral method, a nucleic acid encoding an interleukin comprising IL-2, IL-4, IL-7, IL-10, IL-15, IL-21, and combinations thereof, thereby producing genetically modified TILs;
(d) expanding the genetically modified TILs in a second culture medium to produce a therapeutic population of genetically modified TILs; and
(e) harvesting the therapeutic population of genetically modified TILs.

### Claim 3 (depends on 2)

The method of claim 2, wherein the tumor tissue is processed into a plurality of tumor fragments, each fragment having a volume of about 1 mm3 to about 27 mm3.

### Claim 4 (depends on 2)

The method of claim 2, wherein the first culture medium in step (b) comprises about 6000 IU/mL IL-2.

### Claim 5 (depends on 2)

The method of claim 2, wherein the first population of TILs, the second population of TILs, or both, are introduced into a closed system comprising a container having a gas-permeable surface area, and wherein one or more of the following steps are performed in the closed system:
(a) the culturing of step (b);
(b) the introducing of step (c);
(c) the expanding of step (d); or
(d) the harvesting of step (e),
wherein, when two or more of the steps are performed in the closed system, a transition between consecutive steps performed in the closed system occurs without opening the closed system.

### Claim 6 (depends on 2)

The method of claim 2, wherein the culturing of step (b) is performed for about 3 days to about 14 days.

### Claim 7 (depends on 2)

The method of claim 2, wherein the expanding of step (d) is performed for about 7 days to about 14 days.

### Claim 8 (depends on 2)

The method of claim 2, further comprising activating the expanded population of TILs prior to step (c) by exposing the TILs to anti-CD3/CD28 beads for about 24 hours to about 5 days.

### Claim 9 (depends on 8)

The method of claim 8, wherein step (c) is carried out after the activating step.

### Claim 10 (depends on 2)

The method of claim 2, wherein step (c) comprises lentiviral transduction of the TILs.

### Claim 11 (depends on 2)

The method of claim 2, wherein step (c) comprises gammaretroviral transduction of the TILs.

### Claim 12 (depends on 2)

The method of claim 2, wherein the nucleic acid encodes IL-15.

### Claim 13 (depends on 2)

The method of claim 2, wherein step (c) further comprises introducing into the TILs a programmable nuclease comprising a CRISPR method, a TALE method, or a zinc finger method.

### Claim 14 (depends on 2)

The method of claim 2, wherein step (c) further causes expression of one or more immune checkpoint genes to be silenced or reduced in at least a portion of the TILs, wherein the one or more immune checkpoint genes comprise one or more of PD-1, CTLA-4, LAG-3, HAVCR2 (TIM-3), Cish, TGFβR2, PKA, TIGIT, CBLB, and combinations thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the one or more immune checkpoint genes comprise PD-1, PD-1 and LAG-3, PD-1 and TIGIT, or PD-1 and CTLA-4.

### Claim 16 (depends on 2)

The method of claim 2, wherein step (d) comprises culturing the genetically modified TILs with antigen-presenting cells (APCs) comprising peripheral blood mononuclear cells (PBMCs), artificial antigen-presenting cells (aAPCs), or a combination thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the APCs comprise aAPCs.

### Claim 18 (depends on 16)

The method of claim 16, wherein step (d) further comprises one or more of IL-2, IL-7, IL-15, and IL-21.

### Claim 19 (depends on 2)

The method of claim 2, further comprising one or more of:
(i) transferring the harvested therapeutic population of TILs to an infusion bag;
(ii) cryopreserving the harvested therapeutic population of TILs using a cryopreservation medium; or
(iii) administering the therapeutic population of TILs to a patient.

### Claim 20 (depends on 2)

The method of claim 2, further comprising administering the therapeutic population of TILs to a patient having a cancer comprising one or more of melanoma, ovarian cancer, cervical cancer, NSCLC, lung cancer, bladder cancer, breast cancer, HPV-associated cancer, head and neck cancer, HNSCC, renal cancer, and renal cell carcinoma.

### Claim 21 (depends on 20)

The method of claim 20, wherein the patient receives, prior to administration of the therapeutic population of TILs, a non-myeloablative lymphodepletion regimen comprising administration of cyclophosphamide at about 60 mg/kg/day for two days followed by administration of fludarabine at about 25 mg/m2/day for five days.
